Over the last two decades, significant progress has been made in cancer therapeutics, but significant challenges remain. At the BIO CEO and Investor Digital Conference, experts from leading companies discussed key issues such as. how to drive innovation in oncology, spotting the right investment, the future of PD-1 therapies, and emerging game changers in the field.

Driving Innovation in Oncology: Internal vs. External Pipelines

To drive innovation, Eli Lilly is going after compelling science. Its mantra for getting innovative cancer treatment is “going after actionable targets where there is a clear unmet need based on the current standard of care,” says Avnish Kapoor, Director, Emerging Technology and Innovation